BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
August 05, 2022 06:45 ET | BioNTech SE
Collaboration expands to include development of monospecific antibody candidates to address malignant solid tumors Expanded collaboration leverages Genmab’s proprietary HexaBody® technology platform...
BioNTech und Genmab erweitern globale strategische Kollaboration zur Entwicklung und Vermarktung neuartiger Immuntherapiekandidaten
August 05, 2022 06:45 ET | BioNTech SE
Ausweitung der Kollaboration zur Entwicklung monospezifischer Antikörperkandidaten gegen bösartige solide TumoreKollaboration nutzt Genmabs firmeneigene HexaBody®-Technologieplattform, um neuartige...
BioNTech to Present Data from BNT311 (GEN1046) and BNT131 (SAR441000) Programs at SITC 35th Annual Meeting
October 14, 2020 17:00 ET | BioNTech SE
Data updates from key oncology collaborations to be presentedPreliminary data from the first-in-human trial from intratumoral immunotherapy program BNT131 (SAR441000) in collaboration with Sanofi, to...
CureVac Logo mit Claim RGB.jpg
Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics
December 19, 2019 11:05 ET | CureVac AG
Company Announcement Genmab and CureVac enter broad strategic partnership Companies to conduct joint research on first program; option for Genmab to initiate three additional programs during 5-year...